Structural formula of Apellis

Alpelisib (Alpelisib) is an oral PI3K inhibitor mainly used to treat patients with certain types of advanced breast cancer. Its chemical name is (2S)-N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide. However, the specific chemical structure of Apelvis involves complex molecular structure and chemical knowledge.

Chemical structural formula is a way to describe the arrangement and connection of atoms in a molecule. It is of great significance for understanding the properties, mechanism of action and possible side effects of drugs. As a drug, the structural formula of Apelvis is an important achievement in the drug research and development process and is also an important part of drug patent protection. Apelvis works by inhibiting the PI3K signaling pathway, which plays a key role in cell growth, proliferation and survival. By inhibiting this pathway, Apelvis can slow or stop the growth and spread of breast cancer cells, thereby achieving therapeutic goals.

In terms of medication, the recommended dose of Apelvis is 300 mg once a day (i.e. two 150 mg tablets), which needs to be taken orally with food. When taking, swallow the tablet whole and avoid chewing, breaking or breaking the tablet. The therapeutic benefits of apelvis may be dose-dependent in different patients. For example, a patient taking an empirical dose of 200 mg might gain a 51% advantage, whereas a patient taking a daily dose of more than 100 mg or more than 300 mg once a day might gain only a 22% advantage compared with a patient taking 150 mg twice a day. This suggests that for patients requiring lower doses, a twice-daily dosing regimen may be more appropriate.

In addition, the indications, usage and dosage, side effects and other information of Apelix are also important content that patients and doctors need to pay attention to. This information helps patients use drugs correctly and avoid unnecessary risks, while also helping doctors better evaluate the efficacy and safety of drugs.